C. Robert

Oncology · New England Journal of Medicine · 2005–2020

A researcher in the Science corpus: 43 papers; trusts 3 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 359 citations into it; #709 of 1,698 by trust here, #5 by citations
• Immunology — 200 citations into it
• Molecular Biology — 188 citations into it; #15,507 of 17,773 by trust here, #121 by citations

Whom C. Robert trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Wolchok
2. Antoni Ribas
3. F. Hodi
4. D. Pardoll
5. K. Flaherty
6. C. Blank

Who trusts C. Robert overall

1. Padmanee Sharma
2. J. Wolchok
3. Antoni Ribas
4. Anand Rotte
5. M. Postow
6. J. Haanen
7. E. Buchbinder
8. S. Topalian
9. Georgina V. Long
10. Lieping Chen

Papers from C. Robert's perspective

Ordered by how strongly the researchers C. Robert trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
3. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
4. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (Proceedings of the National Academy of Sciences of the United States of America)
5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
6. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
7. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
8. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (The Lancet Oncology)
9. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (Science)
10. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)

Their papers

• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota (2015) — 3,116 citations
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. (2014) — 1,629 citations
• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011) — 7,483 citations
• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma (2014) — 815 citations
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (2010) — 14,544 citations
• Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) — 1,998 citations
• Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) — 2,453 citations
• Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) — 5,305 citations
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. (2006) — 1,165 citations
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) — 4,405 citations
• Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015) — 2,625 citations
• Nivolumab in previously untreated melanoma without BRAF mutation. (2015) — 5,260 citations
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial (2015) — 1,509 citations
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (2015) — 1,993 citations
• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. (2016) — 1,024 citations
• Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) — 985 citations
• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (2016) — 1,211 citations
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (2015) — 1,127 citations
• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) — 830 citations
• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (2019) — 933 citations